Big players have been carving out a niche in the small but thriving field of poly(ADP-ribose) polymerase (PARP) inhibitors, as long-awaited data roll out that validate the experimental approach.
Hosted on MSN11mon
Novel PARP1 Inhibitor Shows Promise in Breast Cancer"The favorable safety profile of saruparib together with the low rate of dose reductions compared with approved PARP inhibitors may allow patients to remain on treatment longer at an optimal dose ...
New findings could help identify patients likely to become resistant to anti-cancer drugs and aid exploring different ways to ...
Poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, a class of targeted anticancer therapies, prevent genetic ...
Eisbach Bio plans to use a $4.75m grant to advance EIS-12656, a small molecule ALC1 inhibitor to disrupt the genome structure in hard-to-treat cancer cells, says CEO Dr. Adrian Schomburg.
LAE120 is a novel, allosteric and highly potent USP1 inhibitor, displaying monotherapy potency and combination activity with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback